Filing Flows › Altimmune (ALT) › Q3 2025 › vs Q3 2024
Altimmune (ALT) Q3 2025 vs Q3 2024 (year over year)
Altimmune's revenue rose $0 (0%) from $5K in Q3 2024 to $5K in Q3 2025.
Altimmune, Q3 2025: revenue $5K (0% year over year), net loss $19.0M, operating cash flow −$11.9M. The chart draws each line against Q3 2024, the increases inside each band.
Every line
| Line | Q3 2025 | Q3 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $5K | $5K | $0 | 0% |
| Other income, net | $1.8M | $1.9M | −$77K | -4% |
| Net loss | $19.0M | $22.8M | −$3.8M | -17% |
| Costs & expenses | $20.9M | $24.8M | −$3.9M | -16% |
| Operating costs | $20.9M | $24.8M | −$3.9M | -16% |
| Research & development | $15.0M | $19.8M | −$4.8M | -24% |
| General & admin | $5.9M | $5.0M | $935K | +19% |
| Operating cash sources | $19.0M | $22.8M | −$3.8M | -17% |
| Depreciation | $27K | $37K | −$10K | -27% |
| Share-based compensation | $3.6M | $3.1M | $476K | +15% |
| Working capital & other | $3.5M | −$7.4M | $10.9M | — |
| Cash used in operations | $11.9M | $27.1M | −$15.2M | -56% |
| Net loss absorbed | $19.0M | $22.8M | −$3.8M | -17% |
Questions
How much did Altimmune's revenue grow year over year in Q3 2025?
Altimmune's revenue rose $0 (0%) from $5K in Q3 2024 to $5K in Q3 2025.